AstraZeneca’s new drug, BAXFENDY (baxdrostat), has been approved by the FDA to help lower blood pressure in adults who struggle to manage their hypertension with existing medications. This first-in-class treatment works alongside other blood pressure drugs, offering a new option for those who need better control over their numbers. In a recent study involving 796 participants, BAXFENDY demonstrated a significant reduction in blood pressure, with an average decrease of 15.7 mmHg after 12 weeks of treatment.

For people looking to maintain their health as they age, managing blood pressure is crucial. High blood pressure can lead to serious health issues, including heart disease and stroke. With BAXFENDY, individuals who have not found success with other treatments may have a new path to better cardiovascular health. The trial showed that the 2 mg dose was effective, and the 1 mg dose also provided benefits, making it a flexible option for varying patient needs.

While the results are promising, it’s important to note that this drug is still relatively new, and its long-term effects are not yet fully understood. The study showed that BAXFENDY was generally well tolerated, but there are warnings about potential side effects, such as high potassium levels and low sodium levels. The recommended starting dose is 2 mg daily, with a lower dose for those at higher risk of side effects. As AstraZeneca continues to explore more uses for BAXFENDY, this could be a valuable tool for those managing hypertension.

Source: longevity.technology